Linked Life Data

15858436

Source:http://linkedlifedata.com/resource/pubmed/id/15858436

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-4-28
pubmed:abstractText
Individualized selection of the most effective adjuvant (or neoadjuvant) chemotherapy for breast cancer based on the molecular characteristics of the tumor could improve the risk:benefit ratio of current therapies. It could also streamline the development of new regimens for those who are unlikely to benefit from existing drugs. It is expected that combinations of markers will be more informative to predict response than any single gene and may yield regimen-specific predictors. Novel molecular analytical tools, particularly transcriptional profiling, provide a method to test this hypothesis. Several small exploratory studies have shown encouraging results. This article reviews recent progress in this field including experience from the breast cancer pharmacogenomic marker discovery program at the Nellie B. Connally Breast Center of the University of Texas M. D. Anderson Cancer Center. This manuscript is based on a presentation that was given during the Presidential Symposium of the annual meeting of the Japanese Breast Cancer Society in 2004.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1340-6868
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
73-85
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer.
pubmed:affiliation
Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. lpusztai@mdanderson.org
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't